DC inducing and activating agent, DC in-vitro culture method, DC, and CIK

Abstract

The invention provides a DC inducing and activating agent, which comprises small cell lung cancer specificity EGFR and aluminium adjuvant. The EGFR comprises many tumor cell surface structural clusters, and thus EGFR can be used as a simulated antigen to induce and stimulate DC during the culture process of DC so as to maintain the cell activity of DC in a high level. Moreover, an aluminum adjuvant is co-used with EGFR to sustain-release EGFR; the degradation and attenuation of EGFR is avoided, the aluminium adjuvant can interact with DC plasma membrane, and finally the antigen processing and presenting performances of DC are enhanced. The invention also provides a method using the provided DC inducing and activating agent to carry out DC in-vitro culture, DC obtained by the provided method, an application of DC in DC-CIK combined immunization, and CIK prepared through DC-CIK co-culture. Compared with the DC and CIK, which are prepared through a conventional method, the activity and proliferation performance of DC are improved; DC, which has been induced by EGFR, can represent more antigen information, and thus the obtained CIK has a higher activity and stronger performance on killing specific tumors.

Description

technical field [0001] The invention belongs to the technical field of cellular immunity, and in particular relates to a DC inducing activator, a method for culturing DC in vitro, DC and CIK. Background technique [0002] Adoptive immunotherapy is to induce, activate and amplify the precursor cells of self or allogeneic anti-tumor effector cells in vitro with activators such as IL-2, anti-CD3 monoclonal antibody, and specific peptides, and then transfer them to the tumor Patients, so as to improve the anti-tumor immunity of patients, so as to achieve the purpose of treatment. Currently, the most widely used adoptive cellular immunotherapy in clinic is DC (dendritic cell, dendritic cell) therapy, CIK (Cytokine-Induced Killer, cytokine-induced killer cell) therapy and DC-CIK combined immunotherapy. Among them, DC is mainly isolated from bone marrow tissue and blood, has strong ability to capture antigen, present antigen and secrete ability, and can induce a lasting and powerf...

AI Technical Summary

Problems solved by technology

[0005] The purpose of the implementation of the present invention is to overcome the defects of existing cultured DC antigen presentation performance and insufficient growth ability affecting CIK lethality when co-cultured with CIK, and to provide a method that can greatly improve the antigen presentation of DC in the process of in vitro culture A DC-inducing activator capable of maintaining energy efficiency and cell activity while maintaining its degree of differentiation, and a method for using the DC-inducing activator to culture DC in vitro and DC and CIK obtained by the method